🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent opportunity Ashish M. Kamat, MD, MBBS IBCG

Complete vs partial TURBT for #MIBC treatment. fredrik liedberg, Marco Moschini, & Benjamin Pradere join Ashish M. Kamat, MD, MBBS in this discussion on the extent of transurethral resection of bladder tumor (TURBT) needed in muscle-invasive #BladderCancer. #WatchNow on UroToday >

ctDNA as a prognostic biomarker in #BladderCancer treatment decisions. Nimira Alimohamed U Calgary sits down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss the evolution of ctDNA in muscle-invasive bladder cancer management. #WatchNow > bit.ly/3DHx7p5

#NIAGARA study: Durvalumab improves DFS in muscle-invasive #BladderCancer post-cystectomy. Joshua Meeks Northwestern Feinberg School of Medicine sits down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss updated survival data from the NIAGARA study, focusing on disease-free survival results in the cystectomy

Enfortumab vedotin and pembrolizumab demonstrate durable responses in advanced #BladderCancer. Tom Powles Barts Cancer Institute (Queen Mary) joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center sharing 26-month data on enfortumab vedotin + pembrolizumab in advanced urothelial cancer. 💥 50% risk reduction in progression &

Well said. Clear expectations, regular check-ins, and adapting to our team’s strengths are performance multipliers. Align. Assess. Adjust. Repeat.

Nicely done Joshua Meeks Uromigos IBCG

Setting a new bar for pCR: 63.6% after 6 cycles; in cT2 & HER2 3+ patients, 12-month EFS hit 92.5%. Impressive outcomes.

Micropapillary histology in #BladderCancer: a retrospective survival analysis. M. Hassan Alkazemi MD MS UrologyMSK & Hikmat Al Ahmadie Memorial Sloan Kettering Cancer Center join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss a study on micropapillary bladder cancer where findings show worse survival vs. conventional UC (37

Applaud the effort, a word of caution before people rush to use this in practice. Have seen young pts with NMIBC with +ctDNA misclassified as mUC and treated as such - despite no clinical or imaging evidence of mets. The emotional and social fallout for patients and families

Digital therapeutics for LUTS: A randomized trial of app-based treatment. Christian Gratzke Uniklinik Freiburg & Laura Wiemer, MD Kranus Health GmbH join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss an app-based randomized trial for treating lower urinary tract symptoms. This digital therapeutic delivers

Immune infiltration gene signatures predict response to gemcitabine docetaxel vs BCG in #BladderCancer. Michael O'Donnell, MD Carver College of Medicine joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss gene expression signatures and immune infiltration in response to intravesical gemcitabine/docetaxel

Intravesical antibody drug Conjugates for #BladderCancer. Maria Jiang Princess Margaret Cancer Centre sits down with Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to discuss how ADCs are transforming bladder cancer care and reshaping 1L treatment, boosting neoadjuvant response rates & even sparking bladder

The evolving treatment landscape for #NMIBC beyond BCG. Bogdana Schmidt MD, MPH Huntsman Cancer Institute joins Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center in discussing new frontiers in NMIBC: intravesical combos, FGFR3-targeted agents & patient-centered alternatives to radical cystectomy. #WatchNow >

Congratulations to all those who matched into SUO fellowship programs! Welcome to an incredible community of surgeons, scientists, and leaders dedicated to advancing urologic oncology. Excited to see what this next generation will bring to our field.

FDA announced its Commissioner’s National Priority Voucher (CNPV) program to allow drug developers to participate in a novel priority program that shortens its review time from approximately 10-12 months to 1-2 months U.S. FDA fda.gov/news-events/pr…